nach oben

Current Rheumatology Reports

Erschienen in:

01.10.2020 | Systemic Lupus Erythematosus (G Tsokos, Section Editor)

An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice

verfasst von: Jay Patel, Robert Borucki, Victoria P. Werth

Erschienen in: Current Rheumatology Reports | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Understanding the pathogenesis of cutaneous lupus erythematosus (CLE) is an important step in developing new medications and providing effective treatment to patients. This review focuses on novel research within CLE pathogenesis, as well as some of the medications being developed based on this knowledge.

Recent Findings

The subtle differences between systemic lupus erythematosus (SLE) and CLE pathogenesis are highlighted by differences in the circulating immune cells found in each disease, as well as the specific pathways activated by ultraviolet light. Plasmacytoid dendritic cells and the related type I interferon pathway are major components of CLE pathogenesis, and as such, therapies targeting components of this pathway have been successful in recent clinical trials. B cell–depleting therapies have shown success in SLE; however, their role in CLE is less clear. Understanding the differences between these manifestations of lupus allows for the development of therapies that are more effective in skin-specific disease.

Summary

Discovering key pathways in CLE pathogenesis is critical for understanding the clinical features of the disease and ultimately developing new and effective therapies.

Jarukitsopa S, Hoganson DD, Crowson CS, Sokumbi O, Davis MD, Michet CJ Jr, et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. Arthritis Care Res. 2015;67:817–28.

• Grönhagen CM, Fored CM, Granath F, et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011;164:1335–41 This nationwide epidemiologic study identifies the demographics of CLE.PubMed

Petersen MP, Möller S, Bygum A, Voss A, Bliddal M. Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark. Lupus. 2018;27:1424–30.PubMed

Klein R, Moghadam-Kia S, Taylor L, Coley C, Okawa J, LoMonico J, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;64:849–58.PubMedPubMedCentral

Chang AY, Ghazi E, Okawa J, Werth VP. Quality of life differences between responders and nonresponders in the treatment of cutaneous. JAMA Dermatol. 2013;149:104–6.PubMedPubMedCentral

• Vera-Recabarren MA, García-Carrasco M, Ramos-Casals M, et al. Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients. Br J Dermatol. 2010;162:91–101 This study identifies differences in SCLE and CCLE with regards to distribution, lesion types, and immunologic findings.PubMed

Oh EH, Kim EJ, Ro YS, Ko JY. Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea. J Dermatol. 2018;45:436–43.PubMed

Lee LA, Roberts CM, Frank MB, McCubbin V, Reichlin M. The autoantibody response to Ro/SSA in cutaneous lupus erythematosus. Arch Dermatol. 1994;130:1262–8.PubMed

Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev. 2005;4:253–63.PubMed

10.

Callen JP. Drug-induced subacute cutaneous lupus erythematosus. Lupus. 2010;19:1107–11.PubMed

11.

Grönhagen CM, Fored CM, Linder M, Granath F, Nyberg F. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012;167:296–305.PubMed

12.

Watanabe T, Tsuchida T. Classification of lupus erythematosus based upon cutaneous manifestations-dermatological, systemic and laboratory findings in 191 patients. Dermatology. 1995;190:277–83.PubMed

13.

Lin JH, Dutz JP, Sontheimer RD, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol. 2007;33:85–106.PubMed

14.

Crowson AN, Magro C. The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol. 2001;28:1–23.PubMed

15.

David-Bajar KM, Bennion SD, Despain JD, et al. Clinical, histologic, and immunofluorescent distinctions between subacute cutaneous lupus erythematosus and discoid lupus erythematosus. J Invest Dermatol. 1992;99:251–7.PubMed

16.

Ulff-Møller CJ, Svendsen AJ, Viemose LN, Jacobsen S. Concordance of autoimmune disease in a nationwide Danish systemic lupus erythematosus twin cohort. Semin Arthritis Rheum. 2018;47:538–44.PubMed

17.

Sestak AL, Fürnrohr BG, Harley JB, et al. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis. 2011;70 Suppl 1:i37–43.PubMed

18.

• Peschke K, Friebe F, Zimmermann N, et al. Deregulated type I IFN response in TREX1-associated familial chilblain lupus. J Invest Dermatol. 2014;134:1456–9 This study describes the only monogenic cause of CLE.PubMed

19.

Doria A, Cutolo M, Ghirardello A, Zampieri S, Vescovi F, Sulli A, et al. Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum. 2002;47:202–9.PubMed

20.

Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007;56:1251–62.PubMed

21.

Colasanti T, Maselli A, Conti F, Sanchez M, Alessandri C, Barbati C, et al. Autoantibodies to estrogen receptor α interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus. Arthritis Rheum. 2012;64:778–87.PubMed

22.

Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626–38.PubMed

23.

Trancart M, Cavailhes A, Balme B, Skowron F. Anastrozole-induced subacute cutaneous lupus erythematosus [3]. Br J Dermatol. 2008;158:628–9.PubMed

24.

Scofield RH, Bruner GR, Namjou B, Kimberly RP, Ramsey-Goldman R, Petri M, et al. Klinefelter’s syndrome (47, XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum. 2008;58:2511–7.PubMedPubMedCentral

25.

Cooney CM, Bruner GR, Aberle T, Namjou-Khales B, Myers LK, Feo L, et al. 46,X,del(X)(q13) Turner’s syndrome women with systemic lupus erythematosus in a pedigree multiplex for SLE. Genes Immun. 2009;10:478–81.PubMedPubMedCentral

26.

Wang J, Syrett CM, Kramer MC, Basu A, Atchison ML, Anguera MC. Unusual maintenance of X chromosome inactivation predisposes female lymphocytes for increased expression from the inactive X. Proc Natl Acad Sci U S A. 2016;113:E2029–38.PubMedPubMedCentral

27.

• Syrett CM, Paneru B, Sandoval-Heglund D, et al. Altered X-chromosome inactivation in T cells may promote sex-biased autoimmune diseases. JCI Insight. 2019;4:E126751 This study investigates X inactivation effects on T cells and links to increased autoimmunity in females.PubMedCentral

28.

Souyris M, Cenac C, Azar P, et al. TLR7 escapes X chromosome inactivation in immune cells. Sci Immunol. 2018;3:Eaap8855.PubMed

29.

Skonieczna K, Woźniacka A, Czajkowski R, Styczyński J, Krenska A, Robak E, et al. X-linked TLR7 gene polymorphisms are associated with diverse immunological conditions but not with discoid lupus erythematosus in Polish patients. Postepy Dermatol Alergol. 2018;35:26–32.PubMedPubMedCentral

30.

• Laffont S, Rouquié N, Azar P, et al. X-chromosome complement and estrogen receptor signaling independently contribute to the enhanced TLR7-mediated IFN-α production of plasmacytoid dendritic cells from women. J Immunol. 2014;193:5444–52 This study highlights sex differences in TLR7 activation and plasmacytoid dendritic cells.PubMed

31.

Liang Y, Tsoi LC, Xing X, Beamer MA, Swindell WR, Sarkar MK, et al. A gene network regulated by the transcription factor VGLL3 as a promoter of sex-biased autoimmune diseases. Nat Immunol. 2017;18:152–60.PubMed

32.

• Billi AC, Gharaee-Kermani M, Fullmer J, et al. The female-biased factor VGLL3 drives cutaneous and systemic autoimmunity. JCI Insight. 2019;4:e127291 This study highlights the possible role of VGLL3 in mediating CLE and sex differences.PubMedCentral

33.

•• Morris DL, Fernando MMA, Taylor KE, et al. MHC associations with clinical and autoantibody manifestations in European SLE. Genes Immun. 2014;15:210–7 This study identifies MHC associations for SLE and CLE that may offer predictive roles to disease initiation and propogation.PubMedPubMedCentral

34.

Osmola A, Namysł J, Jagodziński PP, Prokop J. Genetic background of cutaneous forms of lupus erythematosus: update on current evidence. J Appl Genet. 2004;45:77–86.PubMed

35.

MILLARD LG, ROWELL NR, RAJAH SM. Histocompatibility antigens in discoid and systemic lupus erythematosus. Br J Dermatol. 1977;96:139–44.PubMed

36.

Kunz M, Konig IR, Schillert A, et al. Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. Exp Dermatol. 2015;24:510–5.PubMed

37.

Millard TP, Kondeatis E, Cox A, Wilson AG, Grabczynska SA, Carey BS, et al. A candidate gene analysis of three related photosensitivity disorders: cutaneous lupus erythematosus, polymorphic light eruption and actinic prurigo. Br J Dermatol. 2001;145:229–36.PubMed

38.

•• Ruiz-Larrañaga O, Migliorini P, Uribarri M, et al. Genetic association study of systemic lupus erythematosus and disease subphenotypes in European populations. Clin Rheumatol. 2016;35:1161–8 This is a study that identifies genetic phenotypes in CLE.PubMed

39.

Järvinen TM, Hellquist A, Koskenmies S, Einarsdottir E, Koskinen LLE, Jeskanen L, et al. Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus. Exp Dermatol. 2010;19:123–31.PubMed

40.

Racila DM, Sontheimer CJ, Sheffield A, Wisnieski JJ, Racila E, Sontheimer RD. Homozygous single nucleotide polymorphism of the complement C1QA gene is associated with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus. Lupus. 2003;12:124–32.PubMed

41.

Werth VP, Zhang W, Dortzbach K, Sullivan K. Association of a promoter polymorphism of tumor necrosis factor-α with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol. 2000;115:726–30.PubMed

42.

Achtman JC, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Arthritis Res Ther. 2015;17:182.PubMedPubMedCentral

43.

Skonieczna K, Czajkowski R, Kaszewski S, et al. Genetic similarities and differences between discoid and systemic lupus erythematosus patients within the Polish population. Postepy Dermatol Alergol. 2017;34:228–32.PubMedPubMedCentral

44.

Levy SB, Pinnell SR, Meadows L, Snyderman R, Ward FE. Hereditary C2 deficiency associated with cutaneous lupus erythematosus: clinical, laboratory, and genetic studies. Arch Dermatol. 1979;115:57–61.PubMed

45.

Agnello V, Gell J, Tye MJ. Partial genetic deficiency of the C4 component of complement in discoid lupus erythematosus and urticaria/angioedema. J Am Acad Dermatol. 1983;9:894–8.PubMed

46.

Lipsker D, Hauptmann G. Cutaneous manifestations of complement deficiencies. Lupus. 2010;19:1096–106.PubMed

47.

Sanchez E, Nadig A, Richardson BC, Freedman BI, Kaufman KM, Kelly JA, et al. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis. 2011;70:1752–7.PubMedPubMedCentral

48.

Järvinen TM, Hellquist A, Koskenmies S, Einarsdottir E, Panelius J, Hasan T, et al. Polymorphisms of the ITGAM gene confer higher risk of discoid cutaneous than of systemic lupus erythematosus. PLoS One. 2010;5:e14212.PubMedPubMedCentral

49.

Solé C, Domingo S, Ferrer B, et al. MicroRNA expression profiling identifies miR-31 and miR-485-3p as regulators in the pathogenesis of discoid cutaneous lupus. J Invest Dermatol. 2019;1:51–61.

50.

Luo Y, Zhang X, Zhao M, Lu Q. DNA demethylation of the perforin promoter in CD4+ T cells from patients with subacute cutaneous lupus erythematosus. J Dermatol Sci. 2009;56:33–6.PubMed

51.

Luo Y, Zhao M, Lu Q. Demethylation of promoter regulatory elements contributes to CD70 overexpression in CD4+ T cells from patients with subacute cutaneous lupus erythematosus: experimental dermatology • Original article. Clin Exp Dermatol. 2010;35:425–30.PubMed

52.

•• Biazar C, Sigges J, Patsinakidis N, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2013;12:444–54 This is a multicenter analysis of SLE patients identifying epidemiology of CLE.PubMed

53.

Foering K, Chang AY, Piette EW, Cucchiara A, Okawa J, Werth VP. Characterization of clinical photosensitivity in cutaneous lupus erythematosus. J Am Acad Dermatol. 2013;69:205–13.PubMedPubMedCentral

54.

• Patsinakidis N, Wenzel J, Landmann A, et al. Suppression of UV-induced damage by a liposomal sunscreen: a prospective, open-label study in patients with cutaneous lupus erythematosus and healthy controls. Exp Dermatol. 2012;21:958–61 This study utilized UV provocation to investigate photosensitivity and the type I IFN system in CLE.PubMed

55.

Liu Y, Xu M, Min X, Wu K, Zhang T, Li K, et al. TWEAK/Fn14 activation participates in Ro52-mediated photosensitization in cutaneous lupus erythematosus. Front Immunol. 2017;8:651.PubMedPubMedCentral

56.

Zahn S, Graef M, Patsinakidis N, Landmann A, Surber C, Wenzel J, et al. Ultraviolet light protection by a sunscreen prevents interferon-driven skin inflammation in cutaneous lupus erythematosus. Exp Dermatol. 2014;23:516–8.PubMed

57.

Wang PW, Hung YC, Lin TY, Fang JY, Yang PM, Chen MH, et al. Comparison of the biological impact of UVA and UVB upon the skin with functional proteomics and immunohistochemistry. Antioxidants. 2019;8:569.PubMedCentral

58.

Hill LL, Ouhtit A, Loughlin SM, Kripke ML, Ananthaswamy HN, Owen-Schaub LB. Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science. 1999;285:898–900.PubMed

59.

Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med. 1996;183:2645–56.PubMed

60.

• Skopelja-Gardner S, An J, Tai J, et al. The early local and systemic type I interferon responses to ultraviolet B light exposure are cGAS dependent. Sci Rep. 2020;10 This study identifies UVB exposure–related STING and type I IFN induction.

61.

•• Sarkar MK, Hile GA, Tsoi LC, et al. Photosensitivity and type i IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018;77:1653–64 This study identifies IFNκ as an UV-induced initial type I IFN capable of CLE induction in a mice model.PubMedPubMedCentral

62.

Piette EW, Foering KP, Chang AY, Okawa J, ten Have T, Feng R, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol. 2012;148:317–22.PubMed

63.

White PC, Hirschfeld J, Milward MR, Cooper PR, Wright HJ, Matthews JB, et al. Cigarette smoke modifies neutrophil chemotaxis, neutrophil extracellular trap formation and inflammatory response-related gene expression. J Periodontal Res. 2018;53:525–35.PubMed

64.

Qiu SL, Zhang H, Tang QY, Bai J, He ZY, Zhang JQ, et al. Neutrophil extracellular traps induced by cigarette smoke activate plasmacytoid dendritic cells. Thorax. 2017;72:1084–93.PubMed

65.

• Lowe G, Henderson CL, Grau RH, et al. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011;164:465–72 This is a review of DI-CLE that highlights medication associations.PubMed

66.

Dalle Vedove C, Simon JC, Girolomoni G. Medikamenteninduzierter Lupus erythematodes unter besonderer Berücksichtigung von Hautmanifestationen und Anti-TNFα-Therapeutika. J Ger Soc Dermatol. 2012;10:889–97.

67.

Marzano AV, Tavecchio S, Menicanti C, et al. Drug-induced lupus erythematosus. G Ital Dermatol Venereol. 2014;149:301–9.PubMed

68.

Vaglio A, Grayson PC, Fenaroli P, Gianfreda D, Boccaletti V, Ghiggeri GM, et al. Drug-induced lupus: traditional and new concepts. Autoimmun Rev. 2018;17:912–8.PubMed

69.

Fiorentino DF. The yin and yang of TNF-α inhibition. Arch Dermatol. 2007;143:233–6.PubMed

70.

Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006;25:383–92.PubMed

71.

Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med. 1991;115:178–83.PubMed

72.

Rönnblom LE, Alm GV, Öberg KE. Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J Intern Med. 1990;227:207–10.PubMed

73.

Wenzel J, Zahn S, Mikus S, Wiechert A, Bieber T, Tüting T. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol. 2007;157:752–7.PubMed

74.

Dey-Rao R, Sinha AA. Genome-wide transcriptional profiling data from chronic cutaneous lupus erythematosus (CCLE) peripheral blood. Data Brief. 2015;2:39–41.PubMed

75.

Braunstein I, Klein R, Okawa J, Werth VP. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol. 2012;166:971–5.PubMedPubMedCentral

76.

Sinha AA, Dey-Rao R. Genomic investigation of lupus in the skin. J Investig Dermatol Symp Proc. 2017;18:S75–80.PubMed

77.

Niewold TB, Hua J, Lehman TJA, Harley JB, Crow MK. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8:492–502.PubMedPubMedCentral

78.

Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol. 2018.

79.

Crow MK, Olferiev M, Kirou KA. Type I interferons in autoimmune disease. Annu Rev Pathol. 2019;14:369–93.PubMed

80.

Meller S, Winterberg F, Gilliet M, Müller A, Lauceviciute I, Rieker J, et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum. 2005;52:1504–16.PubMed

81.

Stannard JN, Reed TJ, Myers E, Lowe L, Sarkar MK, Xing X, et al. Lupus skin is primed for IL-6 inflammatory responses through a keratinocyte-mediated autocrine type I interferon loop. J Invest Dermatol. 2017;137:115–22.PubMed

82.

Zahn S, Rehkämper C, Kümmerer BM, Ferring-Schmidt S, Bieber T, Tüting T, et al. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNλ) in cutaneous lupus erythematosus. J Invest Dermatol. 2011;131:133–40.PubMed

83.

Lauffer F, Jargosch M, Krause L, Garzorz-Stark N, Franz R, Roenneberg S, et al. Type I immune response induces keratinocyte necroptosis and is associated with interface dermatitis. J Invest Dermatol. 2018;138:1785–94.PubMed

84.

Elkon KB. Cell death, nucleic acids, and immunity: inflammation beyond the grave. Arthritis Rheumatol. 2018;70:805–16.PubMedPubMedCentral

85.

Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 2008;19:3–19.PubMedPubMedCentral

86.

Yin Q, Xu X, Lin Y, Lv J, Zhao L, He R. Ultraviolet B irradiation induces skin accumulation of plasmacytoid dendritic cells: a possible role for chemerin. Autoimmunity. 2014;47:185–92.PubMed

87.

Vermi W, Lonardi S, Morassi M, Rossini C, Tardanico R, Venturini M, et al. Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology. 2009;214:877–86.PubMed

88.

• Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005;115:407–17 In vitro study demonstrating a CD32-mediated pDC immune complex uptake in LE.PubMedPubMedCentral

89.

Eloranta ML, Lövgren T, Finke D, Mathsson L, Rönnelid J, Kastner B, et al. Regulation of the interferon-α production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 2009;60:2418–27.PubMed

90.

Saadeh D, Kurban M, Abbas O. Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases. Exp Dermatol. 2016;25:415–21.PubMed

91.

Båve U, Alm GV, Rönnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer. J Immunol. 2000;165:3519–26.PubMed

92.

Lövgren T, Eloranta ML, Båve U, Alm GV, Rönnblom L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50:1861–72.PubMed

93.

Scholtissek B, Zahn S, Maier J, Klaeschen S, Braegelmann C, Hoelzel M, et al. Immunostimulatory endogenous nucleic acids drive the lesional inflammation in cutaneous lupus erythematosus. J Invest Dermatol. 2017;137:1484–92.PubMed

94.

Kuhn A, Herrmann M, Kleber S, Beckmann-Welle M, Fehsel K, Martin-Villalba A, et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum. 2006;54:939–50.PubMed

95.

Biermann MHC, Veissi S, Maueröder C, Chaurio R, Berens C, Herrmann M, et al. The role of dead cell clearance in the etiology and pathogenesis of systemic lupus erythematosus: dendritic cells as potential targets. Expert Rev Clin Immunol. 2014;10:1151–64.PubMed

96.

• Kato Y, Park J, Takamatsu H, et al. Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type i IFN production in systemic lupus erythematosus. Ann Rheum Dis. 2018;77:1507–15 This study brings attention to microvesicles and their contribution to LE and antigen presentation.PubMedPubMedCentral

97.

Thim-uam A, Prabakaran T, Tansakul M, et al. Inhibition of Sting rescues lupus disease by the regulation of Lyn-mediated dendritic cell differentiation. BioRxiv. 2019:PPR99303.

98.

• Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3 This study identifies the cross-talk between neutrophils and plasmacytoid dendritic cells via NETosis.

99.

Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol. 2010;184:3284–97.PubMedPubMedCentral

100.

Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol. 2011;187:538–52.PubMedPubMedCentral

101.

Porat A, Giat E, Kowal C, He M, Son M, Latz E, et al. DNA-mediated interferon signature induction by SLE serum occurs in monocytes through two pathways: a mechanism to inhibit both pathways. Front Immunol. 2018;9:2824.PubMedPubMedCentral

102.

Clancy RM, Markham AJ, Reed JH, Blumenberg M, Halushka MK, Buyon JP. Targeting downstream transcription factors and epigenetic modifications following Toll-like receptor 7/8 ligation to forestall tissue injury in anti-Ro60 associated heart block. J Autoimmun. 2016;67:36–45.PubMed

103.

Murayama G, Chiba A, Kuga T, et al. Inhibition of mTOR suppresses IFNα production and the STING pathway in monocytes from systemic lupus erythematosus patients. Rheumatology. 2020:Keaa060.

104.

• Catalina MD, Bachali P, Geraci NS, et al. Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus. Commun Biol. 2019;2 This study identifies type I IFN gene expression at a system level and identifies a role for monocytes.

105.

Méndez-Flores S, Hernández-Molina G, Enríquez AB, et al. Cytokines and effector/regulatory cells characterization in the physiopathology of cutaneous lupus erythematous: a cross-sectional study. Mediat Inflamm. 2016;2016:7074829.

106.

Méndez-Flores S, Hernández-Molina G, Azamar-Llamas D, Zúñiga J, Romero-Díaz J, Furuzawa-Carballeda J. Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus. Cytokine. 2019;119:95–112.PubMed

107.

Jabbari A, Suárez-Fariñas M, Fuentes-Duculan J, Gonzalez J, Cueto I, Franks AG Jr, et al. Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis. J Invest Dermatol. 2014;134:87–95.PubMed

108.

Heine G. A shift in the Th1/Th2 ratio accompanies the clinical remission of systemic lupus erythematosus in patients with end-stage renal disease. Nephrol Dial Transplant. 2002;17:1790–4.PubMed

109.

Mok MY, Wu HJ, Lo Y, et al. The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol. 2010;37:2046–52.PubMed

110.

• Coias J, Marzuka A, Hosler GA, et al. T-cell polarization differs in various stages of discoid lupus erythematosus skin. Br J Dermatol. 2019;182:1291–3 This study shows that T cell phenotypes in CLE may change depending on the stage of disease.PubMed

111.

Biswas PS, Aggarwal R, Levesque MC, Maers K, Ramani K. Type I interferon and T helper 17 cells co-exist and co-regulate disease pathogenesis in lupus patients. Int J Rheum Dis. 2015;18:646–53.PubMed

112.

Muhammad Yusoff F, Wong KK, Mohd RN. Th1, Th2, and Th17 cytokines in systemic lupus erythematosus. Autoimmunity. 2020;53:8–20.PubMed

113.

Tanasescu C, Balanescu E, Balanescu P, Olteanu R, Badea C, Grancea C, et al. IL-17 in cutaneous lupus erythematosus. Eur J Intern Med. 2010;21:202–7.PubMed

114.

Dey-Rao R, Smith JR, Chow S, et al. Differential gene expression analysis in CCLE lesions provides new insights regarding the genetics basis of skin vs. systemic disease. Genomics. 2014;104:144–55.PubMed

115.

•• Zeidi M, Desai K, Chen KL, et al. 1004 Increased tissue-resident memory T (TRM) cells and STAT3 expression in cutaneous lupus erythematosus patients refractory to antimalarials. J Invest Dermatol. 2019;139:S174 This abstract identifies differences in CLE patients responding and not responding to antimalarials.

116.

Wenzel J, Uerlich M, Wörrenkämper E, et al. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol. 2005;153:1011–5.PubMed

117.

Grassi M, Capello F, Bertolino L, Seia Z, Pippione M. Identification of granzyme B-expressing CD-8-positive T cells in lymphocytic inflammatory infiltrate in cutaneous lupus erythematosus and in dermatomyositis. Clin Exp Dermatol. 2009;34:910–4.PubMed

118.

Simoni Y, Diana J, Ghazarian L, Beaudoin L, Lehuen A. Therapeutic manipulation of natural killer (NK)T cells in autoimmunity: are we close to reality? Clin Exp Immunol. 2013;171:8–19.PubMedPubMedCentral

119.

•• Wouters CHP, Diegenant C, Ceuppens JL, et al. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship. Br J Dermatol. 2004;150:693–700 This study shows differences in circulating immune cells of CLE patients compared with SLE.PubMed

120.

Zahran AM, Abdel-Rahim MH, Elsayh KI, Hassanien MM, Mahran SA, Hetta HF. Natural killer and natural killer T cells in juvenile systemic lupus erythematosus: relation to disease activity and progression. Arch Immunol Ther Exp. 2019;67:161–9.

121.

Tang X, Zhang B, Jarrell JA, Price JV, Dai H, Utz PJ, et al. Ly108 expression distinguishes subsets of invariant NKT cells that help autoantibody production and secrete IL-21 from those that secrete IL-17 in lupus prone NZB/W mice. J Autoimmun. 2014;50:87–98.PubMedPubMedCentral

122.

Yoshiga Y, Goto D, Segawa D, et al. Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis. Int J Mol Med. 2008;22:369–74.PubMed

123.

Mathias LM, Harff M, Orth V, et al. Invariant natural killer T cells are reduced in peripheral blood of bullous pemphigoid patients and accumulate in lesional skin. Arch Dermatol Res. 2019.

124.

Bosma A, Abdel-Gadir A, Isenberg DA, Jury EC, Mauri C. Lipid-antigen presentation by CD1d + B cells is essential for the maintenance of invariant natural killer T cells. Immunity. 2012;36:477–90.PubMed

125.

Araújo JAP, Mesquita D, Cruvinel W d M, et al. Th17 cells and CD4 + multifunctional T cells in patients with systemic lupus erythematosus. Rev Bras Reumatol. 2016;56:28–36.

126.

Webster KE, Kim HO, Kyparissoudis K, Corpuz TM, Pinget GV, Uldrich AP, et al. IL-17-producing NKT cells depend exclusively on IL-7 for homeostasis and survival. Mucosal Immunol. 2014;7:1058–67.PubMed

127.

Olson CM, Bates TC, Izadi H, et al. Local production of IFN-γ by invariant NKT cells modulates acute Lyme carditis. J Immunol. 2009;182:3728–34.PubMedPubMedCentral

128.

McKnight CG, Morris SC, Perkins C, et al. NKT cells contribute to basal IL-4 production but are not required to induce experimental asthma. PLoS One. 2017;12:E0188221.PubMedPubMedCentral

129.

Dubey AK, Handu SS, Dubey S, et al. Belimumab: first targeted biological treatment for systemic lupus erythematosus. J Pharmacol Pharmacother. 2011;2:317–9.PubMedPubMedCentral

130.

Quelhas Da Costa R, Aguirre-Alastuey ME, Isenberg DA, et al. Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018;154:1432–40.PubMedPubMedCentral

131.

Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIver H, Pease CT, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol. 2015;67:1586–91.PubMed

132.

Magro CM, Segal JP, Crowson AN, Chadwick P. The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol. 2010;37:659–71.PubMed

133.

O’Brien JC, Hosler GA, Chong BF. Changes in T cell and B cell composition in discoid lupus erythematosus skin at different stages. J Dermatol Sci. 2017;85:247–9.PubMed

134.

Lauwerys BR, Van Snick J, Houssiau FA. Serum IL-12 in systemic lupus erythematosus: absence of p70 heterodimers but presence of p40 monomers correlating with disease activity. Lupus. 2002;11:384–7.PubMed

135.

Dai J, Liu B, Chua DJ, et al. Essential roles of IL-12 and dendritic cells but not IL-23 and macrophages in lupus-like diseases initiated by cell surface HSP gp96. Eur J Immunol. 2007;37:706–15.PubMed

136.

Wang D, Drenker M, Eiz-Vesper B, Werfel T, Wittmann M. Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus. Arthritis Rheum. 2008;58:3205–15.PubMed

137.

Salvi V, Vermi W, Cavani A, Lonardi S, Carbone T, Facchetti F, et al. IL-21 may promote granzyme B-dependent NK/plasmacytoid dendritic cell functional interaction in cutaneous lupus erythematosus. J Invest Dermatol. 2017;137:1493–500.PubMed

138.

Dai H, He F, Tsokos GC, Kyttaris VC. IL-23 limits the production of IL-2 and promotes autoimmunity in lupus. J Immunol. 2017;199:903–10.PubMedPubMedCentral

139.

Larosa M, Zen M, Gatto M, Jesus D, Zanatta E, Iaccarino L, et al. IL-12 and IL-23/Th17 axis in systemic lupus erythematosus. Exp Biol Med. 2019;244:42–51.

140.

Chaichian Y, Wallace DJ, Weisman MH. A promising approach to targeting type 1 IFN in systemic lupus erythematosus. J Clin Invest. 2019;129:958–61.PubMedPubMedCentral

141.

•• Werth VP, Merola JF, Furie R, et al. 1081 BIIB059, a monoclonal antibody targeting BDCA2, decreases type I interferon-related genes transcriptional activity in subjects with systemic lupus erythematosus (SLE) and active cutaneous LE (CLE). J Invest Dermatol. 2018;138:S183 This is a clinical abstract for a novel BDCA2 antibody to target plasmacytoid dendritic cells in SLE and CLE.

142.

Casey KA, Guo X, Smith MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med. 2018;5:E000286corr1.

143.

Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211–21.PubMed

144.

Vashisht P, Borghoff K, O’Dell JR, Hearth-Holmes M. Belimumab for the treatment of recalcitrant cutaneous lupus. Lupus. 2017;26:857–64.PubMed

145.

Salle R, Chasset F, Kottler D, Picard-Dahan C, Jannic A, Mekki N, et al. Belimumab for refractory manifestations of cutaneous lupus: a multicenter, retrospective observational study of 16 patients. J Am Acad Dermatol. 2020;S0190–9622:30923–3.

146.

•• Albrecht J, Taylor L, Berlin JA, et al. The CLASI (cutaneous lupus erythematosus disease area and severity index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125:889–94 This study created the CLASI system for standardized disease activity measurements across patients and studies.PubMedPubMedCentral

147.

Klein R, Moghadam-Kia S, LoMonico J, Okawa J, Coley C, Taylor L, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147:203–8.PubMedPubMedCentral

Titel: An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice
verfasst von: Jay Patel
Robert Borucki
Victoria P. Werth
Publikationsdatum: 01.10.2020
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 10/2020
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-020-00946-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2020

Lipid-lowering Therapies in Myositis

How Imaging Can Assist with Diagnosis and Monitoring of Disease in Myositis

Turning the Page in Osteoarthritis Assessment with the Use of Ultrasound

Opioid Use and Total Joint Replacement

Vasculitides in HIV Infection